IMPACT OF CHEMOTHERAPY ON THE STANDARD SOLVENTS AND AUTOLOGOUS LIQUID TISSUES ON CYTOKINE STATUS AND NEUTROPHILS OF PERIPHERAL BLOOD OF OVARIAN CANCER PATIENTS

Abstract

Chemotherapeutic treatment using standard solvents is stopped in every fourth ovarian cancer patient because of significant side effects. The autohemochemotherapy method alters the pharmacokinetics of the drug, and significantly reduces the frequency and severity of side effects. In order to compare the effects of neoadjuvant chemotherapy using autologous liquid tissues or standard solvents on cytokine status and neutrophils in the peripheral blood we evaluated the number of neutrophils and their ability to generate reactive oxygen species, and levels of interleukin-1p, IL-1Ra, IL-6, IL-10, IL-18 and TNF-a in 244 primary stage III-IV ovarian cancer patients during chemotherapy according to the AP scheme (cisplatin 75 mg/m2, doxorubicin 50 mg/m2) with infusion by standard intravenous method or as autohemochemotherapy. We established that the effectiveness of chemotherapy was associated with the redox status of neutrophils and cytokine status of peripheral blood, registered prior to neoadjuvant chemotherapy. For patients with tumor progression, increased absolute and relative number of neutrophils with reduced ability to produce reactive oxygen species is significant. For patients with a lack of tumor response, significant are the high levels of serum IL-10 and IL-18. For patients with complete or partial tumor response, significant is the decrease of IL-6 level, compared to the norm. No significant differences in neutrophil and cytokine status in both modes of infusion of chemodrugs have been established. Thus, serum IL-10, IL-18 and IL-6 may be used to predict tumor response to neoadjuvant chemotherapy according to the AP scheme.